Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

VJOncology

Reading the signals

The future is foreseeable, if you know where to look

- PMLiVE

US scientists still wary of Gottlieb’s industry ties

Pharma professionals undertake survey conducted by SAB

- PMLiVE

Microbiome specialist Rebiotix chalks up C. diff trial success

Drug therapy can prevent recurrent infections

A safe place to talk about Crohn’s

Published in eyeforpharma April 2017 by Mariel Metcalfe

Inizio

culture-cannot-be-global-cover

Culture cannot be global: doing business outside your comfort zone

Dorottya Okros of Blue Latitude Health talks through the common communication and negotiation pitfalls of working with Eastern Europe and the CIS for British presenters.

Blue Latitude Health

- PMLiVE

Neurocrine bags FDA approval for first tardive dyskinesia drug

Ingrezza edges ahead of Teva’s rival drug Austedo

Bristol Myers Squibb logo

Apexigen and BMS team up for lung cancer immunotherapy trial

Opdivo and APX005M used together may improve immune reaction

Patient Assistance Programme Evaluation for Cardiovascular Conditions

Our client had launched a self-injection treatment for cardiovascular conditions and were creating an accompanying Patient Assistance Programme (PAP) to educate patients in the use and uptake of this product.Read the case...

Inizio

What next for the treatment of Psoriasis in Europe?

Research Director Laurent Chanroux investigates the changing market dynamics in Psoriasis in Europe.

Inizio

- PMLiVE

The driving force behind Momentum Strategy

An internet search on what makes a business successful delivers countless promises to reveal the secrets behind sustained growth. The strategies of well-known companies provide valuable case studies that have...

Lucid Group Communications Limited

- PMLiVE

Private equity firms agree deal to take over Stada

Cinven and Bain Capital beat out competition from Advent International

National Institute for Health and Care Excellence NICE logo

NICE turns down Opdivo for head and neck cancer

BMS’s nivolumab proves too costly for the NHS

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links